# Phase 2 Small Cell Lung Carcinoma trials: 91 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 91 trials in phase 2 for Small Cell Lung Carcinoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Small Cell Lung Carcinoma trials: 91 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/small-cell-lung-carcinoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 91
- Recruiting or not yet: 91
- Read on: November 19, 2026

## Trials

The 25 newest of 91, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 2, 2026 | NCT07909863 | Low-Dose Radiotherapy Plus Adebrelimab and Chemotherapy for Extensive-Stage Small Cell Lung Cancer | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Not yet recruiting | Small Cell Lung Cancer (SCLC), SCLC, Extensive Stage | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909863) |
| September 15, 2026 | NCT07819591 | Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | SCLC, Recurrent | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07819591) |
| September 4, 2026 | NCT07803848 | Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor... | AIO-Studien-gGmbH | Phase 2 | Recruiting | Small-cell Lung Cancer | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07803848) |
| September 2, 2026 | NCT07798947 | A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 2 | Recruiting | Limited-stage Small-cell Lung Cancer | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07798947) |
| August 12, 2026 | NCT07759856 | NK Cells Plus ICI for SCLC Maintenance | Tianjin First Central Hospital | Phase 2 | Recruiting | Small Cell Lung Cancer | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07759856) |
| June 17, 2026 | NCT07654400 | A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer | Biokin (Shanghai) Biopharmaceutical Co., Ltd. | Phase 2 | Recruiting | Extensive-stage Small-cell Lung Cancer | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07654400) |
| June 11, 2026 | NCT07640932 | Lurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung Cancer | Yonsei University | Phase 2 | Not yet recruiting | Carcinoma, Small Cell Lung | 69 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07640932) |
| June 3, 2026 | NCT07623642 | A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or... | GV20 Therapeutics | Phase 2 | Not yet recruiting | Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms, Prostatic Neoplasms, Squamous Cell Carcinoma of Head and... | 227 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623642) |
| May 13, 2026 | NCT07583511 | Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study | Sun Yat-sen University | Phase 2 | Recruiting | Small-cell Lung Cancer | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07583511) |
| April 27, 2026 | NCT07551635 | SMARCA4/2 Inhibitor for POU2F3-Positive SCLC | Dana-Farber Cancer Institute | Phase 2 | Recruiting | Small Cell Lung Cancer | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07551635) |
| April 23, 2026 | NCT07547332 | Nab-Paclitaxel Combined With Local Therapy in Relapsed SCLC | Shanghai Pulmonary Hospital, Shanghai, China | Phase 2 | Not yet recruiting | Small Cell Lung Cancer, Extensive Stage Small Cell Lung Cancer (ES-SCLC) | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07547332) |
| April 20, 2026 | NCT07538271 | A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | SCLC, Extensive Stage | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07538271) |
| April 20, 2026 | NCT07538258 | Benmelstobart Plus Anlotinib, Chemotherapy and Thoracic Radiation for Limited-Stage Small Cell Lung Cancer | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Limited-stage Small Cell Lung Cancer (LS-SCLC) | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07538258) |
| March 30, 2026 | NCT07501169 | Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC) | Sichuan University | Phase 2 | Not yet recruiting | Extensive-stage Small Cell Lung Cancer (ES-SCLC) | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07501169) |
| March 17, 2026 | NCT07476287 | Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With... | Pfizer | Phase 2 | Recruiting | Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms, Carcinoma... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07476287) |
| March 12, 2026 | NCT07465757 | A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC) | Puma Biotechnology, Inc. | Phase 2 | Recruiting | Small Cell Lung Cancer ( SCLC ) | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07465757) |
| March 10, 2026 | NCT07459634 | A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC | Jazz Pharmaceuticals | Phase 2 | Recruiting | Extensive-stage Small-cell Lung Cancer | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07459634) |
| February 20, 2026 | NCT07423585 | Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer | Sponsor not shown (see the record) | Phase 2 | Recruiting | Extensive Stage Lung Small Cell Carcinoma | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07423585) |
| February 11, 2026 | NCT07402343 | Tarlatamab for SCLC Brain Metastases | Maastricht University Medical Center | Phase 2 | Recruiting | Small Cell Lung Cancer, Brain Metastases, Adult | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07402343) |
| February 10, 2026 | NCT07398560 | Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An... | The Third Affiliated Hospital of Harbin Medical University | Phase 2 | Not yet recruiting | Small Cell Lung Cancer | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07398560) |
| February 5, 2026 | NCT07388875 | Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC | China Medical University, China | Phase 2 | Not yet recruiting | Extensive-Stage Small Cell Lung Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07388875) |
| January 29, 2026 | NCT07376499 | Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune... | China Medical University, China | Phase 2 | Not yet recruiting | Small Cell Lung Cancer | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07376499) |
| January 28, 2026 | NCT07373964 | A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor... | China Medical University, China | Phase 2 | Recruiting | Small Cell Lung Cancer | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07373964) |
| January 22, 2026 | NCT07358676 | A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy... | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Recruiting | Small Cell Lung Cancer (SCLC), SCLC, Extensive Stage | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07358676) |
| January 22, 2026 | NCT07357532 | Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD | Peking University Cancer Hospital & Institute | Phase 2 | Not yet recruiting | Small Cell Lung Carcinoma | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07357532) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Shanghai Pulmonary Hospital, Shanghai, China | 5 |
| Peking University Cancer Hospital & Institute | 4 |
| Fujian Cancer Hospital | 3 |
| Sun Yat-sen University | 3 |
| China Medical University, China | 3 |
| Tianjin Medical University Cancer Institute and Hospital | 3 |
| Shanghai Chest Hospital | 2 |
| National Cancer Institute (NCI) | 2 |
| Sichuan University | 2 |
| [Puma Biotechnology, Inc.](https://specstream.ai/data/clinical-trials/company/puma-biotechnology-inc) | 2 |
| [Sichuan Baili Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd) | 2 |
| Guangzhou Institute of Respiratory Disease | 2 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 2 |
| SWOG Cancer Research Network | 1 |
| Tianjin First Central Hospital | 1 |
| Memorial Sloan Kettering Cancer Center | 1 |
| PrECOG, LLC. | 1 |
| Regina Elena Cancer Institute | 1 |
| Gruppo Oncologico Italiano di Ricerca Clinica | 1 |
| AHS Cancer Control Alberta | 1 |
| Zhejiang Cancer Hospital | 1 |
| University of Maryland, Baltimore | 1 |
| SUNHO（China）BioPharmaceutical CO., Ltd. | 1 |
| London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 1 |
| Harbin Medical University | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 45 |
| United States | 24 |
| Spain | 6 |
| Italy | 5 |
| Germany | 4 |
| South Korea | 4 |
| France | 3 |
| Japan | 3 |
| Taiwan | 3 |
| Canada | 2 |
| Belgium | 2 |
| Israel | 2 |
| Poland | 2 |
| Bulgaria | 1 |
| Portugal | 1 |
| United Kingdom | 1 |
| Australia | 1 |
| Brazil | 1 |
| Hong Kong | 1 |
| India | 1 |
| Serbia | 1 |
| Turkey (Türkiye) | 1 |
| Netherlands | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Irrigation contractors in the United States](https://specstream.ai/data/businesses/irrigation-contractors/united-states)
- [Indian restaurants in the United States](https://specstream.ai/data/businesses/indian-restaurants/united-states)
- [Hong Kong style cafes in the United States](https://specstream.ai/data/businesses/hong-kong-style-cafes/united-states)
- [Gutter contractors in the United States](https://specstream.ai/data/businesses/gutter-contractors/united-states)
- [Garage door companies in the United States](https://specstream.ai/data/businesses/garage-door-companies/united-states)
- [Fire protection companies in the United States](https://specstream.ai/data/businesses/fire-protection-companies/united-states)
